Celgene, Juno to develop new immunotherapies for cancer and autoimmune diseases
The deal will see the firms use T cell therapeutic strategies to develop treatments for these patients with an initial focus on Chimeric Antigen Receptor Technology (CAR-T) and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.